Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Refractory Solid Tumors|Advanced Triple Negative Breast Cancers|Metastatic Triple Negative Breast Cancers
Interventions: DRUG: Talazoparib|DRUG: Selinexor
Sponsor: National University Hospital, Singapore